--- title: "Baxter | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.96 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/294353897.md" datetime: "2026-07-30T11:19:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294353897.md) - [en](https://longbridge.com/en/news/294353897.md) - [zh-HK](https://longbridge.com/zh-HK/news/294353897.md) --- # Baxter | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 2.96 B Revenue: As of FY2026 Q2, the actual value is USD 2.96 B, beating the estimate of USD 2.796 B. EPS: As of FY2026 Q2, the actual value is USD 0.24. EBIT: As of FY2026 Q2, the actual value is USD 222 M. ### Dividend Information Baxter International Inc. declared a quarterly cash dividend of $0.01 per share of common stock, payable on October 1, 2026, to stockholders of record as of August 28, 2026. ### Second Quarter 2026 Financial Highlights #### Company-wide Performance (Continuing Operations) - **Worldwide Sales**: Baxter International Inc. reported worldwide sales of $2.96 billion, marking an increase of 5% on both a reported and organic basis compared to the prior year. - **U.S. Sales**: U.S. sales were $1.6 billion, up 4% on both a reported and organic basis. - **International Sales**: International sales reached $1.4 billion, increasing 7% on a reported basis and 5% on an organic basis. - **Net Income (U.S. GAAP)**: Net income totaled $135 million. - **Adjusted Net Income Attributable to Baxter Stockholders**: Adjusted net income attributable to Baxter stockholders was $281 million, a 2% increase from $276 million in the prior year. - **Gross Margin**: The gross margin was $1,032 million, up 4% from $991 million in the prior year, representing 34.9% of net sales, a decrease of 0.4 percentage points. - **Operating Income**: Operating income was $217 million, a 14% increase from $191 million in the prior year, representing 7.3% of net sales, an increase of 0.5 percentage points. - **Adjusted Operating Income**: Adjusted operating income was $421 million, reflecting a -0% change from $423 million in the prior year. - **Operating Costs**: - **Selling, General and Administrative Expenses**: $735 million, up 2% from $718 million in the prior year, representing 24.8% of net sales. - **Research and Development Expenses**: $129 million, down -4% from $134 million in the prior year, representing 4.4% of net sales. - **Free Cash Flow**: Free cash flow was $181 million for the second quarter. #### Segment Revenue (Second Quarter 2026) - **Medical Products & Therapies**: Total sales were $2.1 billion, increasing 7% on a reported basis and 5% on an organic basis. - **Infusion Therapies & Platforms**: $1,745 million, up 6% (reported) and 4% (organic). - **Advanced Surgery**: $331 million, up 12% (reported and organic). - **Healthcare Systems & Technologies**: Total sales were $801 million, increasing 4% on both a reported and organic basis. - **Care & Connectivity Solutions**: $502 million, up 6% (reported) and 5% (organic). - **Front Line Care**: $299 million, up 2% (reported and organic). - **Other**: Sales were $83 million, a -15% reported change and 0% organic change. ### First Half 2026 Financial Highlights #### Company-wide Performance (Continuing Operations) - **Net Sales**: Total net sales for the six months ended June 30, 2026, were $5,661 million, a 4% increase from $5,435 million in the prior year. - **Net Income (U.S. GAAP)**: Net income for the six months was $111 million, a -49% change from $217 million in the prior year. - **Adjusted Net Income Attributable to Baxter Stockholders**: Adjusted net income attributable to Baxter stockholders was $471 million, a -21% change from $596 million in the prior year. - **Gross Margin**: The gross margin was $1,923 million, up 4% from $1,852 million in the prior year, representing 34.0% of net sales, a decrease of 0.1 percentage points. - **Operating Income**: Operating income was $283 million, a 14% increase from $249 million in the prior year, representing 5.0% of net sales, an increase of 0.4 percentage points. - **Adjusted Operating Income**: Adjusted operating income was $718 million, a -12% change from $815 million in the prior year. - **Free Cash Flow**: Free cash flow was $257 million for the first half of the year, compared to - $144 million in the prior year. - **Cash Flows from Operations**: Cash flows from operations were $510 million, up from $118 million in the prior year. #### Segment Revenue (First Half 2026) - **Medical Products & Therapies**: Total sales were $3,996 million, increasing 5% on a reported basis and 2% on an organic basis. - **Infusion Therapies & Platforms**: $3,361 million, up 4% (reported) and 1% (organic). - **Advanced Surgery**: $635 million, up 13% (reported) and 11% (organic). - **Healthcare Systems & Technologies**: Total sales were $1,506 million, increasing 2% on a reported basis and 1% on an organic basis. - **Care & Connectivity Solutions**: $937 million, up 4% (reported) and 3% (organic). - **Front Line Care**: $569 million, a -0% reported change and -1% organic change. - **Other**: Sales were $159 million, a -1% reported change and 0% organic change. ### Outlook / Guidance Baxter International Inc. raised its full-year 2026 financial outlook, now expecting reported sales growth from continuing operations to be between 3% and 4%. Organic sales growth from continuing operations is projected to be between 2% and 3%. Adjusted earnings from continuing operations per diluted share are forecast to range from $1.95 to $2.15. ### Related Stocks - [BAX.US](https://longbridge.com/en/quote/BAX.US.md) ## Related News & Research - [Baxter International (NYSE:BAX) Updates FY 2026 Earnings Guidance](https://longbridge.com/en/news/294370014.md) - [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md) - [Baxter Q2 revenue rises 5%, beats analyst estimates](https://longbridge.com/en/news/294355455.md) - [Baxter Earnings: What To Look For From BAX](https://longbridge.com/en/news/294145212.md) - [BAX: Q2 sales up 5% to $2.96B; adjusted EPS $0.56; full-year outlook raised](https://longbridge.com/en/news/294359757.md)